申请人:Isis Pharmaceuticals, Inc.
公开号:US10676738B2
公开(公告)日:2020-06-09
The present disclosure provides double stranded nucleic acid comprising first and second oligonucleotides wherein the second oligonucleotide is complementary to the first oligonucleotide. At least one of the first and second oligonucleotides comprises a 5′ modified nucleoside or 5′ modified nucleotide having Formula IIb:
wherein Bx is a heterocyclic base moiety, T2 is an internucleoside linking group linked to one of the oligonucleotides, and each of q1 to q7 are selected from a list of substituents. In certain embodiments, T2 is a phosphodiester or phosphorothioate linkage and formula IIb is a 5′-nucleotide. In certain embodiments, T2 is a non-phosphate linkage and formula IIb is a 5′-nucleoside. In certain embodiments, the present double stranded nucleic acid provides oligonucleotides that are expected to hybridize to a portion of a target RNA resulting in loss of normal function of the target RNA.
本公开提供了包含第一和第二寡核苷酸的双链核酸,其中第二寡核苷酸与第一寡核苷酸互补。第一和第二寡核苷酸中至少有一个包含5′修饰的核苷或5′修饰的核苷酸,其分子式为IIb:
其中 Bx 是杂环碱基,T2 是与寡核苷酸之一连接的核苷内连接基团,q1 至 q7 均选自一系列取代基。在某些实施方案中,T2 是磷酸二酯或硫代磷酸酯连接,式 IIb 是 5′-核苷酸。在某些实施方案中,T2 是非磷酸连接,式 IIb 是 5′-核苷。在某些实施方案中,本发明的双链核酸提供的寡核苷酸可望与靶 RNA 的一部分杂交,导致靶 RNA 失去正常功能。